Agios Pharmaceuticals, Inc. (AGIO) News
Filter AGIO News Items
AGIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AGIO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AGIO News From Around the Web
Below are the latest news stories about AGIOS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AGIO as an investment opportunity.
FDA Accepts Agios' sNDA for Pyrukynd in ThalassemiaIf approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7. |
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-ThalassemiaCAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for PYRUKYND® (mitapivat) for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The review classific |
How to Navigate the Stock and Bond Markets in 2025We asked 10 investing and economic experts for their recommendations as Donald Trump returns to power. Here’s what they said. |
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentat |
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell DiseaseCAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the European Commission has adopted a positive decision for the designation of mitapivat, an oral, small molecule PK activator, as an orphan medicinal product (OMP) for the treatment of sickle cell disease. Earlier, in November 2020, the U.S. Food and Drug Administration (FD |
Here's Why Agios Stock Plummeted More Than 20% on MondayThe fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients. |
Agios Pharmaceuticals price target raised to $75 from $53 at ScotiabankScotiabank raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $75 from $53 and keeps an Outperform rating on the shares. The firm increased its price target on the stock given the promising results presented for its phase 3 ENERGIZE-T study as well as its announcement it filed for the regulatory approval of mitapivat for the treatment of thalassemia in four regions, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking f |
Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' DrugShares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company's thalassemia treatment, mitapivat. |
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Dependent Alpha- and Beta-Thalassemia – – Company Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European |
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |